Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel (ERP). Institutions are invited to submit an application as outlined in the specific RFP.
This RFP reflects Pfizer’s commitment to advancing research, innovation, a n d training for medical, nursing, and allied health professionals.
The goal of this RFP is to offer salary support for Dermatology and/or Allergy Fellowship programs. It is our intent to support fellowship programs at institutions with expertise in inflammatory and immune-mediated dermatological disorders and have a strong focus on clinical practice, research, and education to further the understanding of inflammatory skin diseases, such as atopic dermatitis and alopecia areata. In addition, as the US demographics shift to become more racially diverse, the need to understand skin of color unmet needs will continue to increase. Therefore, programs that prioritize diversity, equity, and inclusion (DEI) principles in dermatology will also be considered.
Full Proposal Deadline: Jan. 24, 2022
Geographic Scope: United States
• Accredited, US-based academic institution. • Do not include the name of the potential fellow(s) in application materials. This grant will be awarded to an institution, not an individual. • Institutions with fellowship programs that include independent research and a strong mentoring program. Clinical training may be included in the program but is not required. • No aspect of the fellowship program can benefit Pfizer’s business or a Pfizer asset. • Examples of independent research include: observational studies and outcomes research studies where the primary focus is the scientific understanding of disease; use of screening tools and their impact on improvement of patient health. o Examples of research that would not be eligible include research involving the study and/or evaluation of any pharmaceutical product and basic science and/or fundamental research (in animal model, in-vitro, etc.). • Examples of clinical training include: educational time with an interdisciplinary team in review of case examples and relevant didactic training as well as use of tools for improvement in patient health for specific therapeutic areas or conditions. • Fellow time spent in the clinical setting that is supported through grant funds must not be billed as patient care.
• Grant funding is available to support one fellow for up to a year at a maximum grant award of $80,000. The budget can only include salary and support of the fellow benefits. • Grant funds cannot be used for overhead or indirect costs. • Funding will be awarded to the institution, not an individual. • Fellow time spent in the clinical setting that is supported through grant funds must not be billed as patient care. • No aspect of the fellowship program budget can reflect a benefit to Pfizer’s business or a Pfizer asset.
